Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections
| Autor: | Rajat Kumar, Auro Viswabandya, Fotios V. Michelis, Jeffrey H. Lipton, Maria Queralt Salas, Armin Gerbitz, Dennis Dong Hwan Kim, Jonas Mattsson, Eshetu G. Atenafu, Carol Chen, Ivan Pasic, Wilson Lam, Arjun Datt Law |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Transplantation Conditioning business.industry Post transplant cyclophosphamide Hematopoietic Stem Cell Transplantation Graft vs Host Disease Hematology Matched Unrelated Donor Human leukocyte antigen Anti-thymocyte globulin Oncology Virus Diseases Immunology Medicine Humans business Cyclophosphamide Antilymphocyte Serum Retrospective Studies |
| Zdroj: | Leukemialymphoma. 62(14) |
| ISSN: | 1029-2403 |
| Popis: | This study compares the outcomes before and after reducing the ATG dose from 4.5 to 2 mg/kg, in a combination of PTCy and CsA for GVHD prevention, in 250 patients treated with HLA matched RIC PB-alloHCT (70% received 4.5 mg/kg and 30% received 2 mg/kg). The incidences of grade II-IV and III-IV aGVHD at day +100, and moderate/severe cGVHD at 1-year were 12.6% vs. 20% ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|